Altimmune (NASDAQ:ALT) Given New $24.00 Price Target at UBS Group

Altimmune (NASDAQ:ALT) had its target price dropped by equities research analysts at UBS Group from $26.00 to $24.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other analysts also recently weighed in on the company. JMP Securities cut their target price on Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 10th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Friday, June 27th. B. Riley lowered their price target on Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Friday, June 27th. Finally, The Goldman Sachs Group upgraded Altimmune to a “strong sell” rating in a research report on Thursday, July 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Altimmune presently has a consensus rating of “Moderate Buy” and an average price target of $17.40.

Altimmune Stock Down 1.6%

Shares of Altimmune stock opened at $3.68 on Wednesday. The business’s fifty day moving average price is $4.79 and its two-hundred day moving average price is $5.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 15.85. The company has a market capitalization of $324.80 million, a P/E ratio of -3.12 and a beta of -0.01. Altimmune has a 1-year low of $2.90 and a 1-year high of $11.16.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. As a group, research analysts forecast that Altimmune will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in shares of Altimmune by 214.2% during the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock valued at $34,000 after purchasing an additional 4,598 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in shares of Altimmune during the second quarter valued at $40,000. Prudential Financial Inc. purchased a new stake in shares of Altimmune during the second quarter valued at $43,000. Magnus Financial Group LLC purchased a new stake in shares of Altimmune during the first quarter valued at $50,000. Finally, Headland Capital LLC purchased a new stake in shares of Altimmune during the first quarter valued at $50,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.